EUVIMEDEUVIMED entdecken
Open Access

Effect of Ranibizumab in Patients with Treatment-Naïve Retinopathy of Prematurity

Hina Khalid iD, Tayyaba Gul Malik iD, Arooj Amjad iD, Iqra Khalid iD, Shahid Muhammad iD

Turkish Journal of Ophthalmology · 2025

DOI: 10.4274/tjo.galenos.2025.77992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Ophthalmology, 2025. Verfasst von Hina Khalid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Post-Graduate Medical Institute/Lahore General Hospital, Clinic of Ophthalmology, Lahore, Pakistan. Hauptthemen laut MEDLINE: Ranibizumab, Retinopathy of Prematurity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives: To determine the effect of intravitreal ranibizumab (IVR) in patients with treatment-naïve retinopathy of prematurity (ROP) in terms of disease regression and need for rescue therapy. Materials and Methods: This study evaluated disease regression and rescue therapy requirement in treatment-naïve ROP cases treated with IVR. Among 188 screened patients, 80 had ROP. Thirty-eight patients (76 eyes) with type 1 ROP and aggressive ROP (AROP) were included. Treatment involved a single dose of 0.2 mg ranibizumab injected under aseptic conditions. Patients were monitored post-treatment for up to 6 months. Recurrence of disease was managed with argon laser photocoagulation targeting the peripheral avascular retina. Data analysis utilized t-tests for continuous variables and χ² tests for categorical data, with a significance threshold of p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabRetinopathy of PrematurityHumansMaleFemaleIntravitreal InjectionsAngiogenesis InhibitorsInfant, NewbornGestational AgeTreatment OutcomeFollow-Up StudiesRetrospective StudiesVascular Endothelial Growth Factor ALaser CoagulationDose-Response Relationship, Drug

Stichwörter der Autor:innen

Ranibizumabanti-vascular endothelial growth factorbevacizumabretinopathy of prematurity

Substanzen

RanibizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Post-Graduate Medical Institute/Lahore General Hospital, Clinic of Ophthalmology, Lahore, Pakistan.
  • Post-Graduate Medical Institute/Lahore General Hospital, Clinic of Pediatric, Lahore, Pakistan.

ORCID-Profile: Hina Khalid, Tayyaba Gul Malik, Arooj Amjad, Iqra Khalid, Shahid Muhammad

Zitieren

APA

Khalid, H., Malik, T. G., Amjad, A., Khalid, I., & Muhammad, S. (2025). Effect of Ranibizumab in Patients with Treatment-Naïve Retinopathy of Prematurity. Turkish Journal of Ophthalmology. https://doi.org/10.4274/tjo.galenos.2025.77992

Vancouver

Khalid H, Malik TG, Amjad A, Khalid I, Muhammad S. Effect of Ranibizumab in Patients with Treatment-Naïve Retinopathy of Prematurity. Turkish Journal of Ophthalmology. 2025. doi:10.4274/tjo.galenos.2025.77992

BibTeX
@article{Khalid2025,
  author = {Khalid, Hina and Malik, Tayyaba Gul and Amjad, Arooj and Khalid, Iqra and Muhammad, Shahid},
  title = {Effect of Ranibizumab in Patients with Treatment-Naïve Retinopathy of Prematurity},
  journal = {Turkish Journal of Ophthalmology},
  year = {2025},
  doi = {10.4274/tjo.galenos.2025.77992}
}
Kostenlos starten →